CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Abstract The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials includi...

Full description

Bibliographic Details
Main Authors:	Oliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández-Fernández, Thomas Forst, Juan-Pablo Frias, James R. Gavin, Francesco Giorgino, Per-Henrik Groop, Hiddo J. L. Heerspink, Stephan Herzig, Michael Hummel, George Huntley, Mahmoud Ibrahim, Baruch Itzhak, Stephan Jacob, Linong Ji, Mikhail Kosiborod, Nebosja Lalic, Sofia Macieira, Rayaz A. Malik, Boris Mankovsky, Nikolaus Marx, Chantal Mathieu, Timo D. Müller, Kausik Ray, Helena W. Rodbard, Peter Rossing, Lars Rydén, Petra-Maria Schumm-Draeger, Peter Schwarz, Jan Škrha, Frank Snoek, Frank Tacke, Bruce Taylor, Britta Tendal Jeppesen, Solomon Tesfaye, Pinar Topsever, Tina Vilsbøll, Xuefeng Yu, Eberhard Standl
Format:	Article
Language:	English
Published:	BMC 2024-03-01
Series:	Cardiovascular Diabetology
Subjects:	Cardiovascular disease Chronic kidney disease CGM Diabetes Finerenone GLP-1 RA
Online Access:	https://doi.org/10.1186/s12933-024-02180-8

Similar Items

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
by: Oliver Schnell, et al.
Published: (2021-03-01)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
by: Oliver Schnell, et al.
Published: (2023-03-01)

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
by: Oliver Schnell, et al.
Published: (2022-04-01)

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
by: Oliver Schnell, et al.
Published: (2019-03-01)

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
by: Oliver Schnell, et al.
Published: (2018-02-01)

Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy
by: Shu J, et al.
Published: (2025-02-01)

Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
by: Nejc Piko, et al.
Published: (2024-03-01)

Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
by: Nicholas Chiu, et al.
Published: (2022-04-01)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
by: Shaikh A, et al.
Published: (2022-07-01)

Efficacy of finerenone in reducing heart failure outcomes in patients with history of heart failure: A meta-analysis of randomized controlled trials
by: Vikash Jaiswal, et al.
Published: (2024-12-01)

Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach
by: Elisa Longhitano, et al.
Published: (2024-11-01)

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
by: Jingying Zhou, et al.
Published: (2024-12-01)

2024 update in heart failure
by: Alberto Beghini, et al.
Published: (2025-02-01)

Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: A case report
by: Cai‐Guo Yu, et al.
Published: (2024-09-01)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
by: Tao Jin, et al.
Published: (2023-04-01)

Potassium management with finerenone: Practical aspects
by: Christoph Wanner, et al.
Published: (2022-11-01)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
by: Dimitrios Patoulias, et al.
Published: (2022-02-01)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
by: Raquel González-Blázquez, et al.
Published: (2018-10-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

Role of L‐type Ca2+‐channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue
by: Francesca Schinzari, et al.
Published: (2024-09-01)

A Trial of Finerenone in a Patient with Primary Aldosteronism
by: Sandra Karanović Štambuk
Published: (2024-09-01)

Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease
by: Mohamad Hanouneh, et al.
Published: (2024-06-01)

Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes
by: Jose Luis Górriz, et al.
Published: (2023-07-01)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
by: Argen Mamazhakypov, et al.
Published: (2023-01-01)

Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
by: Sara Erraez, et al.
Published: (2021-05-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

Finerenone in the management of diabetes kidney disease
by: Parijat De, et al.
Published: (2025-02-01)

A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
by: I. S. Khalimov, et al.
Published: (2025-01-01)

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials
by: Yue Du, et al.
Published: (2024-01-01)

Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
by: Franz Schaefer, et al.
Published: (2024-03-01)

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
by: Haitao Zhang, et al.
Published: (2023-08-01)

Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023-01-01)

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
by: Guntram Schernthaner, et al.
Published: (2019-08-01)

Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms
by: Jing Wang, et al.
Published: (2024-09-01)

Cardiorenal benefits of finerenone: protecting kidney and heart
by: José R. González-Juanatey, et al.
Published: (2023-12-01)

Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)
by: Atsushi Tanaka, et al.
Published: (2023-07-01)

Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
by: Deep Dutta, et al.
Published: (2022-01-01)

Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
by: Katharine Barnard-Kelly, et al.
Published: (2025-02-01)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
by: Ulrich Kintscher, et al.
Published: (2023-06-01)

Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
by: Ioannis Bellos, et al.
Published: (2024-12-01)